Bill Haney's lat­est start­up scores deal from Sanofi, its newest Big Phar­ma part­ner, with $54M up­front

A heav­i­ly fi­nanced biotech look­ing to drug RNA with small mol­e­cules is adding yet an­oth­er com­pa­ny to its Big Phar­ma short­list.

Sky­hawk Ther­a­peu­tics, the biotech head­ed by se­r­i­al en­tre­pre­neur and doc­u­men­tary film­mak­er Bill Haney, an­nounced an ex­clu­sive, back end-heavy col­lab deal Tues­day with Sanofi, which will pri­mar­i­ly fo­cus on yet-undis­closed tar­gets in both im­munol­o­gy and on­col­o­gy. Sanofi agreed to pay $54 mil­lion up­front, and if all the mile­stones are reached, that could add up to over $2 bil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER